Self-organizing molecular field analysis on pregnane derivatives as human steroidal 5α-reductase inhibitors

Steroids

Volumn 75, Issue 6, 2010, Pages 411-418

  Aggarwal, Saurabh ^a   Thareja, Suresh ^a   Bhardwaj, Tilak Raj ^a,b   Kumar, Manoj ^a  

^a PANJAB UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

5 Reductase; BPH; SOMFA; Steroid; Testosterone

Indexed keywords

OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; PREGNANE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; VALIDATION PROCESS;

DIHYDROTESTOSTERONE; HUMANS; ISOENZYMES; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PREGNANES; PROSTATE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 77950516649     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2010.02.005     Document Type: Article

References (50)

1. Isaacs J.T. Antagonistic effect of androgen on prostatic cell death. Prostate 5 (1984) 545-557
2. Imperato-McGinley J. 5 alpha-reductase deficiency: human and animal models. Eur Urol 25 (1994) 20-23
3. Djavan B., and Mirone V. The benefits of dual inhibition of 5α reductase. Eur Urol Suppl 5 (2006) 1013-1017
4. Wilson J.D., Griffin J.E., and Russell D.W. Steroid 5α-reductase 2 deficiency. Endocr Rev 14 (1993) 577-593
5. Walsh P.C., Hutchins G.M., and Ewing L.L. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal. J Clin Invest 72 (1983) 1772-1777
6. Silver R.I., Wiley E.L., Davis D.L., Thigpen A.E., Russell D.W., and McConnell J.D. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 152 (1994) 433-437
7. Silver R.I., Wiley E.L., Thigpen A.E., Guileyardo J.M., McConnell J.D., and Russell D.W. Cell type specific expression of steroid 5 alpha-reductase 2. J Urol 152 (1994) 438-442
8. Wright A.S., Thomas L.N., Douglas R.C., Lazier C.B., and Rittmaster R.S. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest 98 (1996) 2558-2563
9. Wilbert D.M., Griffin J.E., and Wilson J.D. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab 56 (1983) 113-120
10. Russell D.W., and Wilson J.D. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem 63 (1994) 25-61
11. Jenkins E.P., Hsieh C.-L., Milatovich A., Normington K., Berman D.M., Francke U., et al. Characterization and chromosomal mapping of a human steroid 5α-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 11 (1991) 1102-1112
12. Thigpen A.E., Davis D.L., Milatovich A., Mendonca B., Imperato-McGinley J., Griffin J.E., et al. Molecular genetics of steroid 5α-reductase 2 deficiency. J Clin Invest 90 (1992) 799-809
13. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., and Russell D.W. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 92 (1993) 903-910
14. Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., et al. Structure of human type II 5α-reductase gene. Endocrinology 131 (1992) 1571-1573
15. Tamura K., Furihata M., Tsunoda T., Ashida S., Takata R., Obara W., et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67 (2007) 5117-5125
16. Uemura M., Tamura K., Chung S., Honma S., Okuyama A., Nakamura Y., et al. Novel 5 alpha-steroid reductase (SRD5a3,type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99 (2008) 81-86
17. Kazutoshi Y., Labrie F., and Luu-The V. Type 3 5-alpha-reductase is an ubiquitous enzyme highly expressed in the brain and strongly inhibited by finasteride and dutasteride. 13th International congress on hormonal steroids and hormones and cancer, vol. 53 (2008) 107
18. Aggarwal S., Thareja S., Verma A., Bhardwaj T.R., and Kumar M. An overview on 5α-reductase inhibitors. Steroids 75 (2010) 109-153
19. Vaughan D., Imperato-McGinley J., McConnell J., Matsumoto A.M., Bracken B., Roy J., et al. Long-term (7 to 8-year) experience with Finasteride in men with benign prostatic hyperplasia. Urology 60 (2002) 1040-1044
20. Bull H.G., Garcia-Calvo M., Andersson S., Baginsky W.F., Chan H.K., Ellsworth D.E., et al. Mechanism-based inhibition of human steriod 5α-reductase by Finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 118 (1996) 2359-2365
21. Voigt W., Fernandez E.P., and Hsia S.L. Transformation of testosterone into 17β-hydroxy-5α-androstan-3-one by microsomal preparations of human skin. J Biol Chem 245 (1970) 5594-5599
22. Voigt W., and Hsia S.L. Further studies on testosterone 5α-reductase of human skin. Structural features of steroid inhibitors. J Biol Chem 248 (1973) 4280-4285
23. Cabeza M., Zambrano A., Heuze I., Carrizales E., Palacios A., Segura T., et al. Novel C-6 substituted and unsubstituted pregnane derivatives as 5α-reductase inhibitors and their effect on hamster flank organs diameter size. Steroids 74 10-11 (2009) 793-802
24. Ramírez E., Cabeza M., Bratoeff E., Heuze I., Pérez V., Valdez D., et al. Synthesis and pharmacological evaluation of new progesterone esters as 5α-reductase inhibitors. Chem Pharm Bull 53 12 (2005) 1515-1518
25. Bratoeff E., Segura T., Recillas S., Carrizales E., Palacios A., Heuze I., et al. Aromatic esters of progesterone as 5α-reductase and prostate growth inhibitors. J Enzyme Inhib Med Chem 24 3 (2009) 655-662
26. Bratoeff E., Sainz T., Cabeza M., Heuze I., Recillas S., Pérez V., et al. Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5α-reductase. J Steroid Biochem Mol Biol 107 1-2 (2007) 48-56
27. Bratoeff E., Cabeza M., Pérez-Ornelas V., Recillas S., and Heuze I. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives as 5α-reductase inhibitors. J Steroid Biochem Mol Biol 111 3-5 (2008) 275-281
28. Pérez-Ornelas V., Cabeza M., Bratoeff E., Heuze I., Sánchez M., Ramírez E., et al. New 5α-reductase inhibitors: in vitro and in vivo effects. Steroids 70 3 (2005) 217-224
29. Cabeza M., Bratoeff E., Heuze I., Rojas A., Teran N., Ochoa M., et al. New progesterone derivatives as inhibitors of 5α-reductase enzyme and prostate cancer cell growth. J Enzyme Inhib Med Chem 21 4 (2006) 371-378
30. Robinson D.D., Winn P.J., Lyne P.D., and Richards W.G. Self-organizing molecular field analysis: a tool for structure-activity studies. J Med Chem 42 4 (1999) 573-583
31. Cramer III R.D., Patteerson D.E., and Bunce J.D. Comparative molecular field analysis (COMFA) effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 18 (1988) 5959-5967
32. Li S., and Zheng Y. Self-organizing molecular field analysis on a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. Int J Mol Sci 7 (2006) 220-229
33. Thareja S., Aggarwal S., Bhardwaj T.R., and Kumar M. Self organizing molecular field analysis on a series of human 5α-reductase inhibitors: unsaturated 3-carboxysteroids. Eur J Med Chem 44 (2009) 4920-4925
34. Aggarwal S., Thareja S., Bhardwaj T.R., and Kumar M. 3D-QSAR studies on unsaturated 4-azasteroids as human 5α-reductase inhibitors: a self organizing molecular field analysis approach. Eur J Med Chem 45 (2010) 476-481
35. 1a-adrenoceptor dihydropyridine antagonists. Bioorg Med Chem 11 (2003) 3945-3951
36. Murthy V.S., and Kulkarni V.M. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 10 (2002) 2267-2282
37. Thareja S., Kokil G., Aggarwal S., Bhardwaj T.R., and Kumar M. Sulphonamides as inhibitors of protein tyrosine phosphatase 1B (PTP 1B): a 3D-QSAR study using SOMFA approach. Chem. Pharm. Bull. 58 4 (2010) in press
38. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. Development and use of quantum mechanical molecular models AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107 (1985) 3902-3909
39. Stewart J. MOPAC: a semiempirical molecular orbital program. J Comput Aid Mol Des 4 (1990) 1-105
40. 1a receptor ligands by the method of comparative molecular field analysis. J Comput Chem 14 (1993) 237-245
41. 2 ligands: a significant model through a combined exploration of structural diversity and methodology. J Med Chem 43 (2000) 1109-1122
42. Xu M., Zhang A., Han S., and Wang L. Studies of 3D-quantitative structure-activity relationships on a set of nitroaromatic compounds: CoMFA, advanced CoMFA and CoMSIA. Chemosphere 48 (2002) 707-715
43. Pedretti A., Villa L., and Vistoli G. VEGA: a versatile program to convert, handle and visualize molecular structures on windows-based PCs. J Mol Graph Model 21 1 (2002) 47-49
44. VEGA ZZ Release 2.0.5.52: http://www.ddl.unimi.it/vega/index2.htm.
45. SOMFA2 v2.0.0 (2006). http://www.bellatrix.pcl.ox.ac.uk/ http://www.bellatrix.pcl.ox.ac.uk/
46. 1-adrenoceptor antagonists. Bioorg Med Chem Lett 15 (2005) 3216-3219
47. Kulkarni S.S., Gediya L.K., and Kulkarni V.M. Three-dimensional quantitative structure activity relationships (3D-QSAR) of antihyperglycemic agents. Bioorg Med Chem Lett 7 (1999) 1475-1485
48. 2!. J Mol Graph Model 20 (2002) 269-276
49. Puntambekar D.S., Giridhar R., and Yadav M.R. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and COMSIA models. Eur J Med Chem 43 (2008) 142-154
50. Thareja S, Aggarwal S, Bhardwaj TR, Kumar M. 3D-QSAR studies on a series of 5-arylidine-2,4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach. Med Chem 2010; 6(1): in press.